Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110). (Q42237113)
Jump to navigation
Jump to search
scientific article published on March 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110). |
scientific article published on March 2014 |
Statements
1 reference
Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110). (English)
1 reference
Danielle P Porter
1 reference
Rima Kulkarni
1 reference
Todd Fralich
1 reference
Michael D Miller
1 reference
Kirsten L White
1 reference
1 March 2014
1 reference
1 reference
65
1 reference
3
1 reference
318-326
1 reference
Identifiers
1 reference
1 reference